AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KJUN 303 min read$IMNN

Imunon, Inc. (IMNN): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Imunon, Inc. (IMNN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0000749647 0000749647 2026-06-29 2026-06-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report

Original reporting
SEC EDGAR 8-K
Published Jun 30, 2026, 8:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 30, 2026, 8:36 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefCorporate actions
Primary signal
$IMNN
Neutral
medium confidence
Mentioned
$IMNN
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$IMNNNeutralLow
01

Why it matters

The company describes an orderly retirement with no disagreements and sets compensation terms for Church’s consulting role and the hourly rate for the new interim CFO via Danforth Health.

02

Market read

This is a governance/finance-leadership update with defined compensation terms; it may affect short-term sentiment but does not introduce new financial guidance or major corporate actions.

03

What to watch

The new interim CFO is provided via Danforth Health under a per-hour rate; traders may watch for follow-on filings (new financing, audit/accounting changes, or additional officer appointments) around the transition date.

Relevance 6/10Novelty 5/10Timing: effective July 1, 2026 for CFO transition

Background

Imunon reported an Item 5.02 8-K detailing the retirement of interim CFO Jeffrey Church and the appointment of an interim CFO effective July 1, 2026.

Company-level read

Ticker impact

$IMNNNeutralMedium confidence
Context

Imunon filed an 8-K announcing interim CFO Jeffrey Church’s retirement effective July 1, 2026 and appointing Josh Blacher as interim CFO.

Expected impact

Likely limited near-term impact; any reaction would be sentiment-driven around continuity of finance leadership rather than fundamentals.

Evidence & confidence

The filing is a routine executive/compensation update (Item 5.02) with no stated operational, financing, or guidance changes; however, leadership continuity can still affect investor perception for small-cap issuers.

Market effects

Sector

Minimal; this is company-specific finance leadership/compensation disclosure rather than a sector catalyst.

Regional

Minimal; no regional macro or cross-border transaction disclosed.

Global

Minimal; no global deal, regulator action, or supply-chain disruption mentioned.

Counterpoint

What could challenge this read

Even without stated disagreements, interim CFO changes can signal internal instability or upcoming financing needs that are not explicitly disclosed in this 8-K.

Key entities

  • issuer
    Imunon, Inc.

    Nasdaq-listed company filing the 8-K (IMNN) regarding CFO transition and compensatory arrangements.

  • executive
    Jeffrey Church

    Interim CFO retiring effective July 1, 2026; continues as a consultant under an amended agreement.

  • executive
    Josh Blacher

    Appointed interim CFO effective July 1, 2026; serves as principal financial officer and principal accounting officer via Danforth Health.

  • service_provider
    Danforth Health, Inc.

    Financial advisory services firm providing the interim CFO under a master services agreement dated June 24, 2026.

Read at source← All news

Related articles

JUL 30
$IMNNMed

EXCLUSIVE: Imunon Outlines Accelerated Timeline, Strong Safety Data for Pivotal Ovarian Cancer Study - Im

Imunon Inc. (NASDAQ:IMNN) updated its pivotal Phase 3 OVATION 3 trial of IMNN-001 in newly diagnosed advanced ovarian cancer. The company said site activation and enrollment are ahead of forecasts, with full enrollment expected by Q2 2029. It reported no cytokine release syndrome or serious immune-related adverse events and noted two interim analyses that could support an early BLA. Shares rose 1.95% to $1.57 premarket.

benzinga.com3 min
JUL 30
$IMNNMed

Imunon, Inc.: IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer

IMUNON (Nasdaq: IMNN) provided an update on its pivotal Phase 3 OVATION 3 trial of IMNN-001 in newly diagnosed advanced ovarian cancer. The company said enrollment is ahead of plan, with a study rate of about 0.5 patients per site per month versus 0.3 planned, and it now expects completion in Q2 2029. It reported no cytokine release syndrome and comparable safety versus control.

finanznachrichten.de4 min
JUN 5
$IMNNMedAI 9/10

Imunon Secures $10 Million Funding Package to Advance Phase 3 Ovarian Cancer Study (IMNN)

Imunon Inc. (NASDAQ:IMNN) said it secured a $10 million financing package to advance its Phase 3 OVATION 3 ovarian cancer trial of IMNN-001. The company will receive $2.5 million via 250 non-redeemable, non-convertible preferred shares and about $7.72 million through two secured promissory notes at 8% and 5% interest, maturing in 18 months. Imunon cited updated Phase 2 survival data.

finance.yahoo.com4 min
AUG 9
$SKHYMed

SK Hynix’s $38 billion buildout has a name attached: Nvidia

SK Hynix (SKHY) approved about 54.3 trillion won (about $38.3B) for two memory plants through 2031, Reuters reported. About 35.2 trillion won funds a DRAM fab in Yongin (Y2) with construction starting July 2027 and first cleanroom June 2029. Remaining 19.1 trillion won supports a NAND plant in Cheongju. Reuters also said it is reviewing further shareholder returns.

yahoo.com6 min
AUG 9
$ITWMed

Illinois Tool Works Authorizes $6 Bln Buyback

Illinois Tool Works (ITW) said its board authorized a new share repurchase program of up to $6 billion. The board also approved a 7% increase in its regular annual cash dividend to $6.88 per share, effective with the Q4 dividend of $1.72 payable Oct. 9, 2026. ITW closed at $296.66 on Friday.

rttnews.com2 min